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Abstract
Deletion of exon 9 from Cullin-3 (CUL3, residues 403–459:
CUL3D403–459) causes pseudohypoaldosteronism type IIE (PHA2E), a
severe form of familial hyperkalaemia and hypertension (FHHt).
CUL3 binds the RING protein RBX1 and various substrate adaptors
to form Cullin-RING-ubiquitin-ligase complexes. Bound to KLHL3,
CUL3-RBX1 ubiquitylates WNK kinases, promoting their ubiquitin-
mediated proteasomal degradation. Since WNK kinases activate
Na/Cl co-transporters to promote salt retention, CUL3 regulates
blood pressure. Mutations in both KLHL3 and WNK kinases cause
PHA2 by disrupting Cullin-RING-ligase formation. We report here
that the PHA2E mutant, CUL3D403–459, is severely compromised in
its ability to ubiquitylate WNKs, possibly due to altered structural
flexibility. Instead, CUL3D403–459 auto-ubiquitylates and loses
interaction with two important Cullin regulators: the
COP9-signalosome and CAND1. A novel knock-in mouse model of
CUL3WT/D403–459 closely recapitulates the human PHA2E phenotype.
These mice also show changes in the arterial pulse waveform,
suggesting a vascular contribution to their hypertension not
reported in previous FHHt models. These findings may explain the
severity of the FHHt phenotype caused by CUL3 mutations
compared to those reported in KLHL3 or WNK kinases.
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Introduction
Blood pressure is controlled in part by the WNK kinase pathway,
which acts to modulate the activity of key cation–chloride
co-transporters in the kidney (Kahle et al, 2008; Alessi et al, 2014).
Considerable insight into this pathway has come from exploring the
molecular basis for mutations described in patients with a rare
monogenic form of hypertension called familial hypertension and
hyperkalaemia [FHHt, also known as pseudohypoaldosteronism
(PHA2); OMIM: 145260]. Mutations in the genes encoding WNK
kinases have been shown to increase protein levels of WNK1 and
WNK4 in the kidney, leading to increased activation of this pathway
(Wilson et al, 2001; Kahle et al, 2008). When activated by phospho-
rylation, the WNK kinases phosphorylate and activate the down-
stream kinases, SPAK (SPS1-related proline/ alanine-rich kinase)
and OSR1 (oxidative stress–responsive kinase 1), which in turn
phosphorylate and activate cation–chloride co-transporters in the
kidney, such as NCC (Na+/Cl co-transporter), which leads to
increased sodium ion reabsorption (Vitari et al, 2005; Delpire &
Gagnon, 2008; Richardson et al, 2008, 2011). It is this up-regulation
of the WNK signalling pathway that is responsible for the salt reten-
tion that drives the hypertension in FHHt. These patients also
present with disturbed plasma electrolytes especially hyperkalaemia
and a metabolic acidosis, partly driven by NCC activation (Boyden
et al, 2012; Osawa et al, 2013; Tsuji et al, 2013; Glover et al, 2014;
McCormick et al, 2014). As FHHt patients are salt-loaded through
NCC activation, the hypertension and electrolyte disturbance
respond to either salt restriction or low doses of thiazide diuretics
(Gordon & Hodsman, 1986; Mayan et al, 2002).
More recently, the ubiquitin–proteasome system (UPS) was
shown to have a critical upstream role in regulating blood pressure
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by modulating WNK kinase levels (Mori et al, 2013; Ohta et al,
2013; Wakabayashi et al, 2013; Wu & Peng, 2013). This was first
suggested when patients with severe forms of FHHt were described
with mutations in Cullin-3 (CUL3; PHA2E), and one of its substrate
adaptors, KLHL3 (PHA2D) (Boyden et al, 2012; Louis-Dit-Picard
et al, 2012; OMIM:145260). CUL3 belongs to the Cullin-RING ligase
(CRL) family that form the largest class of ubiquitin E3 ligases in the
cell. Cullins are elongated proteins, which confer an extended struc-
ture to active CRL complexes (Zheng et al, 2002; Duda et al, 2011).
Through their C-terminus, Cullins constitutively bind to a small
RING finger protein, either RBX1 or RBX2, which forms the catalytic
core of the ligase complex. The binding to various substrate-adaptor
proteins at the N-terminal domain enables CUL3-RBX1 to appropri-
ately ubiquitylate a plethora of cellular substrates (Wee et al, 2005;
Harper & Tan, 2012). In this way, CUL3 acts as an active scaffold to
direct ubiquitylation, as C-terminally bound RBX1 binds ubiquitin-
conjugating E2 enzymes that are charged with ubiquitin, while
simultaneously binding to the substrate adaptor, in this instance
KLHL3. The overall structural rigidity of the Cullin, in particular
between the elongated N-terminus and the globular C-terminus, is
important for the ubiquitin E3 ligase function of the complex. Alter-
ations in the connecting sequence between the Cullin N- and
C-terminus are thought to change the relative positioning of the
RING domain towards the bound substrate, which can prevent
substrate modification (Zheng et al, 2002; Liu & Nussinov, 2011).
Efficient CRL ubiquitylation also requires the modification of a
conserved C-terminal lysine residue (Lys 721 in CUL3) by a single
molecule of the ubiquitin-like protein Nedd8 (Pintard et al, 2003).
This modification, auto-catalysed by CUL3-RBX1, is aided by
Nedd8-E3 ligases (Kurz et al, 2005; Rabut et al, 2011) and alters the
flexibility of the C-terminal Cullin-RBX1 module to activate E3 ligase
activity (Duda et al, 2008; Scott et al, 2014). While neddylation is
required for efficient ubiquitylation, studies show that the cycling
between a neddylated and deneddylated state is crucial in a cellular
context (Cope et al, 2002; Pintard et al, 2003). As such, Cullin inter-
actions with the deneddylation complex COP9-signalosome (CSN), a
metalloprotease, are also required for activity. Another regulator of
CRLs, CAND1, interacts with the N- and C-terminus of Cullins only
in their deneddylated state to promote the exchange of substrate
adaptors (Liu et al, 2002; Goldenberg et al, 2004; Pierce et al, 2013;
Wu et al, 2013; Zemla et al, 2013).
In the context of PHA2, KLHL3 is the critical adaptor that links
the WNK kinases to CUL3-RBX1, enabling CUL3 to directly ubiquity-
late the bound WNK kinase. In earlier work, we and others showed
the KLHL3 mutations described in FHHt (PHA2D) patients disrupt
the formation of the complex and prevent WNK ubiquitylation, lead-
ing to WNK stabilisation and increased flux through the WNK
kinase pathway (Mori et al, 2013; Ohta et al, 2013; Shibata et al,
2013; Wakabayashi et al, 2013; Wu & Peng, 2013; Schumacher
et al, 2014; Susa et al, 2014). Some patients with FHHt have muta-
tions in WNK kinases, which promote WNK stabilisation by
disrupting WNK-KLHL3 interactions (Wakabayashi et al, 2013;
Schumacher et al, 2014) or, in some cases, by the increased expres-
sion of WNK mRNA (Wilson et al, 2001).
While FHHt patients with CUL3, KLHL3 or WNK mutations
present with the same disease, those with mutations in CUL3 display
a more severe phenotype, evident in terms of both an earlier age-of-
onset and the degree of hypertension and electrolyte disturbance
reported (Boyden et al, 2012; Osawa et al, 2013; Tsuji et al, 2013).
To date, all the reported CUL3 PHA2E mutations are heterozygous,
transmit as autosomal dominant traits and result in the deletion of
the amino acids encoded for by exon 9 of the CUL3 mRNA (residues
403–459) (Boyden et al, 2012; Grimm et al, 2012; Osawa et al, 2013;
Tsuji et al, 2013; Glover et al, 2014). Nevertheless, precisely why
and how this truncated form of CUL3 (hereafter referred to as
CUL3D403–459) causes a more severe phenotype is currently unclear.
We have investigated this question using a biochemical in vitro
approach to understand the molecular defects caused by the muta-
tion and a mouse model of PHA2E to better understand the physio-
logical basis of the effects of CUL3D403–459. This has uncovered a
number of critical molecular and physiological factors that enhance
our understanding of Cullin-RING ligase mechanisms, the physiol-
ogy of CUL3, and importantly its pathophysiology in FHHt patients.
Results
CUL3D403–459 forms an active Cullin-RING ligase complex
To investigate the molecular defect of CUL3D403–459, we determined
whether this form of CUL3 was able to build a CRL complex. First,
we established that CUL3D403–459 binds RBX1 similar to CUL3WT, by
showing that both versions of CUL3 form a stable complex with
RBX1 when co-expressed in insect cells (Fig 1A). A second critical
interaction for a functional CRL is the ability to bind substrate-adap-
tor proteins, and in the context of WNK kinase modification, CUL3
must interact with KLHL3 (Lamark & Johansen, 2012; Ji & Prive´,
2013; Canning & Bullock, 2014). The 57-residue deletion in
CUL3D403–459 lies in a structurally distinct domain of CUL3 and
would not be expected to perturb binding to substrate adaptors. We
confirmed that CUL3D403–459 indeed retains the ability to bind KLHL3
by in vitro pull-down assays with purified proteins (Fig 1B). We also
showed this interaction is maintained in a cellular system, using
ectopically expressed FLAG-tagged CUL3 to co-precipitate endoge-
nous KLHL3 in FLAG immunoprecipitates (Fig 1H, lower panel). Thus,
CUL3D403–459 maintains crucial interactions important for ubiquitin-
ligase function. Given this, we tested whether CUL3D403–459-RBX1 also
maintains the ability to hydrolyse the thioester bond between the
catalytic cysteine residue of a recruited E2 enzyme and ubiquitin
(E2~UB), a critical step in ubiquitylation and a measure for catalytic
activity. Using ubiquitin-release assays from charged E2 enzymes,
we show that CUL3D403–459 hydrolyses E2~UB more efficiently than
CUL3WT, demonstrating a functionally intact CUL3D403–459-RBX1
catalytic core, while also suggesting potential hyper-activity
(Fig 1C). Together, these results demonstrate that CUL3D403–459
maintains interactions and basic functionality critical for CRL activity.
Structural modelling suggests CUL3D403–459 is more flexible
than CUL3WT
To better understand how the deletion in CUL3D403–459 may affect
the CRL, we predicted the structure of CUL3, using closely related
Cullin-1 (CUL1; Fig 1D; Appendix Fig S1). The region deleted in
CUL3D403–459 likely forms a three-helical bundle juxtaposed to the
globular C-terminal domain. Removal of these helices would fuse
together two short unstructured regions to create a longer loop,
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which, as well as shortening the elongated structure of the CRL
complex, may increase the flexibility between the two domains. If
correct, this model explains how RBX1 and KLHL3 binding is main-
tained (Munir et al, 2007; Calabrese et al, 2011), while also suggest-
ing the function of the ligase may be compromised due to the
altered relative orientation of the CRL components towards each
other. Studies investigating the structure of CUL1 demonstrated the
importance of a rigid Cullin conformation for substrate ubiquityla-
tion, as increasing the flexibility of CUL1, in an area that
corresponds to the CUL3 deletion, led to strongly decreased
substrate ubiquitylation (Zheng et al, 2002; Appendix Fig S1). It
is therefore possible that due to the presence of a predicted
unstructured flexible loop, CUL3D403–459 may similarly sample non-
productive conformations.
CUL3D403–459 has altered Nedd8-ligase activity and is unable to
interact with the CRL regulators COP9-signalosome and CAND1
Available structural data of CRL proteins bound to Cullin regulators
suggest the deleted region in CUL3D403–459 may also influence neddy-
lation and binding of the CSN (Lingaraju et al, 2014) and of CAND1
(Goldenberg et al, 2004; Fig EV1). This prompted us to examine
whether these interactions are affected by the PHA2E mutation.
To investigate the ability of CUL3D403–459 to be auto-modified
with Nedd8, we used in vitro neddylation assays with purified
CUL3, Nedd8 E1 (APPBP1-UBA3), Nedd8 E2 (UBE2M) and Nedd8.
As Nedd8 forms a covalent isopeptide bond with CUL3, neddylation
can be visualised as a slower-migrating band on SDS–PAGE. We
found CUL3D403–459 retains the ability to auto-neddylate (Fig 1E,
Appendix Fig S2A). However, CUL3D403–459 appears less efficient at
transferring Nedd8, as unlike for CUL3WT, some unmodified
CUL3D403–459 remained even 45 min after neddylation was initiated.
Moreover, while CUL3WT was only mono-neddylated, multiple
Nedd8 molecules were attached to CUL3D403–459 (Fig 1E). Both of
these differences in neddylation are consistent with increased struc-
tural flexibility of CUL3D403–459.
As reported (McCormick et al, 2014), we also noticed that
CUL3D403–459 neddylation is elevated in cells (Fig 1F). CRLs cycle
between neddylated and de-neddylated states to maintain activity
(Pintard et al, 2003). Therefore, the increased cellular neddyla-
tion of CUL3D403–459 could reflect a decrease in de-neddylation
by the isopeptidase CSN. The structure of the CSN bound to
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CUL1 supports this idea, as the Cullin C-terminal domain,
including the region equivalent to residue 403–459 in CUL3,
contacts the CSN subunits directly (Lingaraju et al, 2014). To
investigate this possibility, we blocked neddylation using an inhi-
bitor of the Nedd8-E1 enzyme (MLN4924; Millennium Pharma-
ceuticals) and monitored CUL3 de-neddylation over time.
Consistent with decreased rates of deneddylation, CUL3D403–459
remained neddylated for longer than CUL3WT (Fig 1G) and also
showed markedly reduced binding to CSN subunits (Fig 1H,
Appendix Fig S2B). As such, the observed elevated Nedd8
modification of CUL3D403–459 in cells is likely due to a combination
of Nedd8 ligation to non-physiological lysine residues and of
reduced CSN de-neddylation.
CRLs must be de-neddylated for a productive interaction with the
substrate-adaptor exchange factor CAND1. Furthermore, the struc-
ture of CUL1 bound to CAND1 suggests that, regardless of neddyla-
tion state, CUL3D403–459 may be unable to form the required critical
interactions (Goldenberg et al, 2004; Pierce et al, 2013; Wu et al,
2013; Zemla et al, 2013). We therefore investigated whether
CUL3D403–459 was indeed defective in binding to CAND1. We treated
cells expressing either FLAG-CUL3WT or FLAG- CUL3D403–459 with
the neddylation inhibitor MLN4924 to force all of CUL3 into the
non-neddylated state and then determined interaction with CAND1
by immunoprecipitation. While CUL3WT strongly bound to CAND1
in these assays, CUL3D403–459 was unable to interact with CAND1
(Fig 2H, Appendix Fig S2B). We confirmed these findings using
in vitro assays with purified proteins (Fig 1I). These data advocate
that structural perturbations prevent CUL3D403–459 from binding to
CAND1. In combination with the impairment of CSN binding, such
defects suggest that the regulation of CUL3D403–459 in cells is likely
severely disrupted.
CUL3D403–459 displays enhanced auto-ubiquitylation
Our data indicate that the regulation of CUL3D403–459 is defective in
cells, and we wanted to test whether its ubiquitylation activity is
similarly affected. McCormick et al suggested that CUL3D403–459 may
stabilise WNK kinases by ectopically degrading the substrate adap-
tor KLHL3, preventing the formation of functional CUL3-KLHL3
complexes (McCormick et al, 2014). Some CRLs are known to ubiq-
uitylate bound substrate adaptors (Wee et al, 2005), and it is feasi-
ble that altering the CUL3 backbone structure could indeed lead to
erroneous ubiquitylation of KLHL3. In our in vitro system, we con-
firmed that CUL3D403–459 directly modified KLHL3 with a greater effi-
ciency than CUL3WT (Fig 2A, Appendix Fig S2C). Interestingly, we
observed that CUL3D403–459 also exhibited markedly increased auto-
ubiquitylation (Fig 2B, Appendix Fig S2D).
Auto-ubiquitylation is often utilised as a read-out for ubiquitin-
ligase activity. In a cellular context, self-modification can lead to
auto-degradation of the ligase (Silke et al, 2005). If CUL3D403–459
Figure 1. CUL3D403–459 forms a functional Cullin-RING ligase with altered activity and is unable to interact with CRL regulators.
A Purified CUL3WT and CUL3D403–459 analysed by SDS–PAGE and Coomassie blue staining, following expression in SF21 cells, and DAC-tag-affinity purification and tag
cleavage (see Materials and Methods). Bands migrating between 62- and 98-kDa protein markers are CUL3WT and CUL3D403–459, respectively, while the band below 17
kDa is Rbx1. The immunoblot for RBX1 is shown on the right. The band in CUL3WT denoted with * is co-purified insect cell CAND1, which was later removed by SEC.
All protein identities were confirmed by mass spectrometry.
B KLHL3 binding to CUL3WT and CUL3D403–459 is comparable as shown by pull-down assays with a KLHL3 resin generated from cross-linking anti-KLHL3 antibody to
Protein G sepharose, and then binding saturating amounts of KLHL3 to the anti-KLHL3 resin (denoted KLHL3R), the control resin (ControlR) is Protein G sepharose (see
Materials and Methods for further detail). CUL3WT or CUL3D403–459 was incubated with either KLHL3R or ControlR at 4°C for 1 h and then washed thrice with 1× PBS,
resin volumes were minimised, and SDS–Laemmli buffer was used to elute protein from resin prior to analysis by SDS–PAGE and staining with colloidal blue.
C UBE2D3~ubiquitin-release assays analysed by non-reducing SDS–PAGE and immunodetection. His-tagged UBE2D3 was charged with ubiquitin by incubation with
ATP and UAE, and charging was stopped by ATP depletion with apyrase. No CUL3 (negative control, lane 1), CUL3WT or CUL3D403–459 was then added to the charged
E2 and the activity of the RING domain, RBX1, monitored by the hydrolysis of ubiquitin from UBE2D3, visualised by immunodetection with anti-His antibody (upper
panel, “~” denotes thioester bond). The lower panel is an immunoblot for CUL3, showing equivalent amount of both CUL3WT and CUL3D403–459 was added to the
reaction mix; over time, the appearance of higher molecular weight bands represents the modification of CUL3 by covalent attachment of ubiquitin. The right two
lanes are control lanes incubated for 10 min with E2~Ubi but then treated with reducing agent prior to SDS–PAGE.
D Structural model of CUL3WT based on the structure of CUL1 (PDB:1LDK), highlighting the residues deleted in the PHA2E mutant which are located close to the
N-terminal domain (NTD) and C-terminal domain (CTD) border, using Phyre2 and Chimera (see Materials and Methods). The NTD is coloured purple, the CTD cyan,
and residues 403–459 orange.
E Time course of in vitro neddylation reactions. Purified NAE, UBE2M and Nedd8 were mixed with either CUL3WT or CUL3D403–459 and incubated at 30°C for the time
indicated. Due to the covalent attachment of Nedd8 (8.6 kDa), modified proteins have decreased mobility. The band shift observed for CUL3WT (lane 1 versus lane 2) is
representative of a single Nedd8 modification, while the multiple bands in the CUL3D403–459 reaction reflect the attachment of up to three Nedd8 molecules (lane 5
versus lane 8).
F HEK-293 cells over-expressing either FLAG-CUL3WT or FLAG-CUL3D403–459 were immunoprecipitated with M2 Flag-binding sepharose, in the presence of a deneddylase
inhibitor (OPT). Extract, cells were lysed in the presence of OPT and clarified by centrifugation. IP:M2, clarified supernatant samples were incubated for 1 h at 4°C
with M2 (anti-Flag) sepharose, then washed with PBS and eluted with SDS–Laemmli buffer, prior to SDS–PAGE and immunodetection with anti-FLAG antibody. Bands
are labelled as follows: 1. CUL3WT, 2. CUL3WT-N8, 3. CUL3D403–459, 4. CUL3D403–459-N8, 5. CUL3D403–459-2(N8).
G Neddylation in HEK-293 cells over-expressing FLAG-CUL3WT or FLAG-CUL3D403–459 was blocked by treatment with a Nedd8-E1-enzyme inhibitor, 3 lM MLN4924
(Millennium Pharmaceuticals), in cells over-expressing FLAG-CUL3WT and FLAG-CUL3D403–459 respectively. Cell extracts were sampled over time in the presence of OPT
to prevent de-neddylation and subjected to SDS–PAGE and immunodetection of the FLAG tag.
H FLAG-CUL3WT or FLAG-CUL3D403–459 was immunoprecipitated with M2-sepharose as described in (F). +MLN4924 indicates cell culture media supplementation with
3 lM MLN4924 for 5 h prior to cell lysis to achieve complete deneddylation of CUL3. Following SDS–PAGE, immunoblotting with COP9 Signalosome (CSN) or CAND1
antibodies determined the interaction between these Cullin regulators and FLAG-CUL3WT and FLAG-CUL3D403–459, respectively.
I GST-CAND1 pull-down assays with CUL3 proteins. Purified GST or GST-CAND1 immobilised on glutathione–sepharose was mixed with either purified CUL3WT or
CUL3D403–459 and incubated at 4°C for 1 h. The sepharose was then washed thrice and eluted from the resin by incubation with SDS–Laemmli buffer prior to SDS–
PAGE and Coomassie staining. CUL3WT but not CUL3D403–459 interacts with CAND1.
Source data are available online for this figure.
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modifies lysine residues inaccessible to CUL3WT, this could explain
the increased auto-ubiquitylation. Alternatively, CUL3D403–459 could
build longer ubiquitin chains on the same lysine residues that are
also targeted by CUL3WT. To explore these possibilities, we
performed in vitro ubiquitylation assays with methylated ubiquitin,
a form of ubiquitin unable to build ubiquitin chains (Kirisako et al,
2006). In these assays, CUL3D403–459 was auto-modified on multiple
lysine residues, while CUL3WT only mono-ubiquitylated one residue
(Fig 2C). Therefore, the observed increase in auto-ubiquitylation is
most likely due to erroneous modification of multiple lysine resi-
dues on CUL3D403–459, which is consistent with an increase in struc-
tural flexibility as suggested by our model. Alternatively, the
mutation may change the active site environment of CUL3, exposing
more lysine residues close to the E2~UB binding site. To distinguish
between these possibilities, we mapped the lysine residues modified
in our in vitro assay system using mass spectrometry. We performed
in vitro auto-ubiquitylation reactions of CUL3 with methylated
ubiquitin for either 5 or 45 min and determined the ubiquitylated
lysine residues by analysing which lysine residue(s) carry di-glycine
remnants after trypsin digest (Fig 2D and E; Kim et al, 2011). Using
this approach, we found that after 5 min, CUL3WT was only
auto-ubiquitylated on a single lysine residue (K336), while ten
lysine residues on CUL3D403–459 were modified (Fig 2D and E). After
running the reaction for 45 min, the modification sites on CUL3WT
had increased to five, all of which were C-terminal to the original
site and contained within the globular C-terminal Cullin domain.
The ubiquitylation sites on CUL3D403–459, however, had increased to
25 sites distributed along the entire length of the protein (most
N-terminal: K47; most C-terminal: K743). These results support our
model that the CUL3 deletion induces increased structural flexibility,
leading to the erroneous auto-ubiquitylation of sites normally not
accessible to CUL3WT (Figs 2E and F and EV2).
CUL3D403–459 cannot ubiquitylate WNK kinases
As CUL3D403–459 is able to more efficiently auto-ubiquitylate itself
and KLHL3, we next asked whether it similarly shows increased
ubiquitylation towards a bound WNK substrate in in vitro ubiquityla-
tion assays using purified components. As we previously showed,
CUL3WT efficiently ubiquitylates WNK kinases in vitro (Fig 3; Ohta
et al, 2013). CUL3D403–459, however, while maintaining the ability to
efficiently modify itself and KLHL3, was not able to modify either
WNK1 or WNK4 (Fig 3A and B). As described for CUL1 (Zheng et al,
2002), increasing the flexibility of the Cullin backbone can lead to a
decrease in substrate modification, while promoting excessive modi-
fication of other CRL components (Zheng et al, 2002). Thus,
increased structural flexibility of CUL3D403–459 may lead to similar
defects. If so, then it becomes important to understand how this
in vitro finding can explain the increased WNK stabilisation found
in vivo. It is possible that only one of the three defects, the lack of
substrate ubiquitylation, the increased Cullin auto-ubiquitylation or
the increased KLHL3 ubiquitylation, is the major driver for the
observed phenotypes. Decisively, KLHL3 levels are not decreased in
the kidney of CUL3WT/D403–459 mice, while the overall CUL3 levels
are lower. This suggests that KLHL3 degradation does not contribute
to the observed PHA2E phenotype, and instead, we propose that
CUL3D403–459 stabilises WNK levels in two ways: firstly, CUL3D403–459
excessively auto-ubiquitylates, leading to its own degradation; and
secondly, any CUL3D403–459 protein that escapes degradation cannot
promote the ubiquitylation of the WNK kinases. Importantly, all
PHA2E patients are heterozygous for the mutation, suggesting that
with respect to blood pressure regulation either CUL3D403–459
behaves as a dominant-negative or CUL3WT is haploinsufficient. Our
data demonstrate that the mutation causes a loss-of-function, so a
dominant-negative effect seems less likely. We also find that in vitro,
equimolar amounts of CUL3D403–459 do not inhibit CUL3WT (Fig 3C),
further supporting the concept of haploinsufficiency.
CUL3WT/D403–459 mice have increased flux through the WNK
kinase pathway and typical FHHt phenotypic features of
electrolyte imbalance
To complement our in vitro findings and to determine more accu-
rately what occurs in PHA2E patients, we engineered a knock-in
(KI) mouse carrying the same exon 9 deletion of CUL3 as reported
in PHA2E pedigrees (CUL3D403–459; Appendix Fig S3). Despite setting
up heterozygous mating pairs, no homozygous KI mice were born
suggesting that, like deletion of the entire coding region of CUL3,
the homozygous deletion of residues 403–459 is lethal (Singer et al,
1999). Nevertheless, all the reported PHA2E pedigrees are heterozy-
gous, so we phenotyped the heterozygous KI mice. Utilising both
immunoblotting of whole kidney lysates and immunofluorescence
Figure 2. CUL3D403–459 displays increased auto-ubiquitylation and ubiquitylation of KLHL3.
A–D In vitro ubiquitylation assays with purified proteins. As ubiquitin is covalently attached to the substrate lysine residue, the appearance of higher molecular weight
protein bands reflects the modification of the protein with ubiquitin. All assays contain purified UBE1, UBE2D3, ubiquitin, 0.1 mM ATP, 1 mM MgCl2 and were
buffered in 50 mM HEPES, 150 mM NaCl and incubated at 30°C for the time indicated. Reactions were stopped by the addition of SDS–Laemmli buffer to a
concentration of 1×. SDS–PAGE, staining with Coomassie blue, or detection with the indicated antibody following immunoblotting enabled the visualisation of
ubiquitylation. (A) to determine the relative modification of KLHL3 by CUL3WT and CUL3D403–459, KLHL3 was included into the reaction at 2× molar concentration
over CUL3WT and CUL3D403–459. (B, C) Reactions serve to determine basal auto-ubiquitylation of CUL3WT or CUL3D403–459 and do not contain KLHL3 or other
potential substrate proteins. Lysine residues on CUL3WT or CUL3D403–459 act as the substrate. (B) High molecular weight bands reflect ubiquitin chain linkages on
CUL3 or the multiple mono-ubiquitylation of a number of CUL3 lysine residues. (C) Activity assays contain methylated ubiquitin, a form of ubiquitin incapable of
forming ubiquitin chains; as such, higher band shifts reflect the attachment of mono-ubiquitin to one more lysine residue on CUL3WT or CUL3D403–459, respectively.
(D) Activity assay performed as in (C) with methyl-ubiquitin, the boxes shown on the gel are indicative of the gel pieces excised for mass spectrometry analysis in (F).
E Schematic representation (to linear residue scale) highlighting the domains of CUL3 and schematic representation of the lysine residues of CUL3WT or CUL3D403–459,
modified at 5 and 45 min, respectively, in the in vitro ubiquitylation assay shown in (D) and as determined by mass spectrometry.
F Structural docking model of CUL3D403–459 based on the structure of full-length CUL1 (1LDK) using Chimera (see Materials and Methods). The NTD is coloured green,
while the CTD is red, and the four panels sample possible positioning of the CTD relative to the NTD in CUL3D403–459, assuming full flexibility of the linker after
deletion of three helices encoded by exon 9.
Source data are available online for this figure.
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confocal microscopy of kidney sections, we determined the relative
abundance and distribution of proteins involved in the WNK signal-
ling pathway. Whole kidney lysate was analysed by immunoblotting
confirming the expression of CUL3 and the presence of an additional
band corresponding to the expected PHA2E form, CUL3D403–459, in
the heterozygous mice (Fig 4A). Increased levels of WNK4 and the
downstream components of the WNK kinase pathway, reported in
other mouse models of FHHt, were also observed (Fig 4A). Specifi-
cally, there were striking increases in both total and phosphorylated
forms of SPAK and NCC (Fig 4A). We also confirmed the expression
of KLHL3 and CUL3 in normal human kidney lysates (Fig 4B). In
the context of our in vitro data, we were especially interested in
examining the levels of KLHL3 and CUL3 in the mouse kidney
(Fig 4A). Definitively, the overall level of KLHL3 was comparable
between CUL3WT/WT and CUL3WT/D403–459 mice. In contrast,
CUL3D403–459 appears to be less abundant than CUL3WT in the
heterozygous mice. These observations suggest that CUL3D403–459
does not promote KLHL3 degradation in vivo and, moreover, that
the lower levels of CUL3D403–459 may be due to the propensity of
CUL3D403–459 to self-modify presumably causing degradation
through the UPS. The lower level of observable CUL3D403–459 may
also be due to non-proteolytic hyper-modification of CUL3D403–459
with either Nedd8 or ubiquitin. Indeed, this may in part be the case,
as incubation of kidney extract at room temperature to promote
de-conjugation of Nedd8 or ubiquitin increased the abundance of
the faster migrating CUL3D403–459 band, but did not restore it to
CUL3WT levels (Fig 4A, lower panel). Regardless of precisely why,
the stabilisation of WNK4 and increased signalling through the
WNK cascade is consistent with a PHA2E model.
Over-activation of the WNK pathway would be expected to
perturb electrolyte homoeostasis. We confirmed this by measuring
urine electrolytes, blood biochemistries and aldosterone levels in
the mice (Figs 4C and D and EV3). The CUL3WT/D403–459 mice
showed the typical electrolyte disturbance of FHHt with hyper-
kalaemia, hyperchloraemia and a compensated metabolic acidosis,
with the pH maintained by an increased respiratory drive to increase
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Figure 3. CUL3D403–459 is unable to ubiquitylateWNK1 orWNK4 kinases in an in vitro system, and this deficiency cannot be rescued by the presence of CUL3WT.
A–C In vitro ubiquitylation assays were performed as described in Figure 2, but with the addition of immunoprecipitated WNK1 in (A), or immunoprecipitated over-
expressed FLAG-WNK4 in (B, C) (see Materials and Methods). The WNK kinases are modified by CUL3WT-KLHL3, with the higher molecular weight smear observed in
anti-WNK1 and anti-FLAG panels representative of multiple ubiquitin molecules being covalently attached to the WNK protein. CUL3D403–459 is unable to modify
WNKs. Samples from the same assay reactions were divided to allow immunodetection of the different protein components modified within the same assay
reaction. (C) CUL3WT, CUL3D403–459 and an equimolar solution CUL3WT:CUL3D403–459 (1:1 Mix) were incubated with KLHL3 and immunoprecipitated FLAG-WNK4 in
ubiquitylation reactions to determine the influence of CUL3D403–459 on the ubiquitylation activity of CUL3WT. Notably, the presence of CUL3D403–459 does not inhibit
WNK ubiquitylation by CUL3WT.
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CO2 removal and hence reduced total CO2 and pCO2 levels. The
mice also had elevated aldosterone levels (Fig 4C) driven by the
hyperkalaemia without pronounced hypervolaemia as evidenced by
similar haematocrit levels (Fig EV3). Hypermagnesaemia and hyper-
phosphataemia were noted on detailed electrolyte analysis of
plasma and urine, which are the converse of the abnormalities
reported in Gitelman syndrome (Fig EV3; Akhtar & Hafeez, 2009;
Rafiqi et al, 2010; Pathare et al, 2012; Ali et al, 2013; Zhang et al,
2015). Additionally, we also found that the CUL3WT/D403–459 mice
have significantly lower body weight and body length relative to the
WT mice (Appendix Fig S4). This is consistent with Gordon’s origi-
nal observation that children with PHA2 may present with a low
percentile body weight and height for their age (Gordon, 1986) and
more recent reports that CUL3WT/D403–459 patients are growth
retarded (Osawa et al, 2013; Tsuji et al, 2013).
WNK4 and SPAK accumulate and form puncta in the distal
convoluted tubule of CUL3WT/D403–459 mice
Using immunofluorescence confocal microscopy of kidney
sections, we studied the distribution of proteins involved in the
WNK kinase cascade in both CUL3WT/WT and CUL3WT/D403–459
mice (Fig 5A). CUL3WT/D403–459 mice showed a similar CUL3 distri-
bution compared to both the WT mice, and to the WT human
kidney (Fig 5A and B). This was in keeping with the abundance
observed in the kidney immunoblots (Fig 4A). In contrast, staining
for WNK4 and SPAK in the CUL3WT/D403–459 mice revealed these
proteins to have a striking punctate appearance in the DCT, but
not in adjacent segments of the nephron including the thick
ascending limb (TAL; Figs 5A and EV4). While WNK1 and OSR1
puncta have been reported in the DCT of SPAK knockout mice,
these were smaller in size and far less numerous (Grimm et al,
2012). As these puncta do not co-localise with the lysosomal
marker LAMP1 or form ubiquitin-containing aggregates (Figs 5A
and EV4), they may represent an accumulation of WNK and SPAK
proteins within a protein-processing compartment, such as the
trans-Golgi network or activation of secondary protein degradation
pathways or storage compartments, due to failed proteasomal
clearance (D’Urso et al, 1998; Lamark & Johansen, 2012; Wolff
et al, 2014).
CUL3WT/D403–459 mice have hypertension and a novel
vascular phenotype
Over-activation of the WNK pathway as observed in our
CUL3WT/D403–459 mice (Figs 4 and 5) should lead to salt retention
and elevated blood pressure. We therefore measured the blood pres-
sure (BP) of the CUL3WT/D403–459 mice using a carotid pressure
transducer catheter under general anaesthesia. Both male and
female CUL3WT/D403–459 mice exhibited significantly higher BP rela-
tive to CUL3WT/WT littermates (Fig 6A).
Strikingly, we also observed a previously unreported haemody-
namic change in the blood pressure trace of the CUL3WT/D403–459
mice. The systolic aortic pressure wave of the heterozygous mice is
augmented, while the diastolic relaxation (s) is significantly slowed
(Munir et al, 2007; Fig 6B). These changes suggest early wave
reflection of the pressure wave and compliance changes consistent
with a stiffened vascular tree. This stiffening could reflect a primary
change in the contractile state of vascular smooth muscle, so to
explore this we studied the in vivo vasoconstrictor responses to
intravenous administration of phenylephrine and angiotensin II
(Fig 6C; Bergaya et al, 2011). The resulting dose–response curves
showed that the maximal constrictor response to both vasopressor
agents was substantially higher in the CUL3WT/D403–459 mice.
CUL3 and KLHL3 are expressed in the mouse and human aorta,
and CUL3WT/D403–459 mice have aortic wall thickening
We also looked for evidence of biochemical changes in the vascula-
ture and confirmed the expression of CUL3 and KLHL3 in mouse
and human aorta by immunoblot analysis (Fig 7A and B, Appendix
Fig S5). Similar to the kidneys (Fig 4A), no differences were seen in
KLHL3 expression between CUL3WT/D403–459 and CUL3WT mice,
while the levels of CUL3 WT protein were lower in CUL3WT/D403–459
aorta. To address the altered contractility in the vessel wall in vivo,
we also measured the level of pMYPT1 in aortic vessel lysates and
showed a significant 1.7-fold increase (Feng et al, 1999; Somlyo &
Somlyo, 2003; Appendix Fig S6). Image analysis of mouse and
human aortae confirmed that both have strong CUL3 staining of the
vascular endothelium and smooth muscle cells of the intimal and
medial layers of the vessel wall (Fig 7C and D). Finally, to explore
◀ Figure 4. CUL3WT/D403–459 mice recapitulate PHAII electrolyte imbalances due to over-activation of the renal WNK4-SPAK pathway.A Western blot of whole kidney lysates from mice culled after a minimum 4-h fast. Following exsanguination after surgery, mouse tissues were rapidly harvested and
stored, samples were then homogenised, clarified and quantified prior to SDS–PAGE. Immunodetection with the antibodies shown highlights elevated signalling
through the WNK kinase pathway in CUL3WT/D403–459 versus CUL3WT mice. The lowest panel is an anti-CUL3 immunoprecipitation of the kidney lysate samples,
whereby the CUL3 antibody was cross-linked to Protein G sepharose and used to affinity purify CUL3WT and CUL3D403–459 from kidney lysates. The samples were
incubated together overnight to allow deneddylation of CUL3 proteins to occur and maximise CUL3 binding to the anti-CUL3 resin. Samples were thoroughly washed
and eluted from the resin prior to SDS–PAGE and immunodetection for CUL3. The IP highlights that CUL3D403–459 is indeed present within the kidney lysate.
B Fresh frozen kidney tissues from transplant patient and donor cadavers were homogenised, clarified and quantified prior to SDS–PAGE. Western blot analysis
confirmed the expression of KLHL3 and CUL3 in normal healthy human kidneys.
C Plasma aldosterone after a minimum 4-h fast was calculated by HTRF (homogeneous time-resolved fluorescence) aldosterone assay. The average aldosterone level
per mouse was calculated from duplicate samples run in parallel on the assay. Blood was rapidly harvested in heparin-coated plasma extraction tubes following
exsanguination after surgery, and samples were snap-frozen for storage. A 58% increase in aldosterone was detected in CUL3WT/D403–459 versus CUL3WT mice
(*P = 0.0245). Two-tailed unpaired Student’s t-test; data are mean  SEM.
D Arterial blood biochemistries after a minimum 4-h fast. Under anaesthesia, the right carotid artery was cannulated to minimise atmospheric exposure of samples
collected for iSTAT blood gas and electrolyte measurements. CUL3WT/D403–459 mice present with abnormal electrolyte homoeostasis compared to CUL3WT mice,
exhibiting hyperkalaemia (***P = 0.0004) and hyperchloraemia (***P = 9.5 × 105) with a compensated metabolic acidosis (P = 0.7766), marked by a decrease in
bicarbonate (HCO3 ) (***P = 3.4 × 10
5), base excess (BE) (***P = 9.1 × 105) and partial pressure of carbon dioxide (pCO2) (***P = 0.0038). Two-tailed unpaired
Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
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further the vascular phenotype, we performed a morphometric anal-
ysis of the aortae of CUL3 mice that confirmed significant thickening
of the vessel wall in the heterozygote mice (Fig 7E). This probably
reflects hyperplasia/hypertrophy of the vascular smooth muscle
cells in the medial layer, as the numbers of elastic laminae were not
significantly different (Fig 7E).
Discussion
This study describes the first successful PHA2E mouse model
involving CUL3 and highlights the molecular differences and defects
of the mutant CUL3 protein. The deletion of 57 amino acids in
CUL3D403–459 does not affect the ability of the bound RING domain
to hydrolyse E2~UB, and as such CUL3D403–459 is still an active E3
ligase. Instead, our structural predictions and experimental findings
suggest that the CUL3D403–459 CRL scaffold lacks a level of rigidity
required for substrate ubiquitylation. Our results are consistent with
a previous report that demonstrated ubiquitylation of the Cullin-1
substrate (p27) was abrogated when a linker was inserted between
the NTD and CTD of the closely related CUL1 protein (Zheng et al,
2002). Thus, the CUL3D403–459 mutation is a novel physiological
example of the importance of this CRL rigidity and to our knowledge
the first example of a human mutation that impedes the scaffolding
function of a Cullin. Our data are consistent with the working
hypothesis that the CUL3D403–459 mutation has increased structural
flexibility. The deletion of three helices fuses together two unstruc-
tured regions, which likely allows greater movement between the
N-terminal and C-terminal domains of the Cullin. This prevents the
complex from successfully directing ubiquitin towards a bound
substrate, and instead, leads to increased auto-ubiquitylation of
CUL3 and KLHL3. Importantly, it appears as if in vivo this auto-
ubiquitylation triggers degradation of the mutant form of the Cullin,
as only relatively low amounts of CUL3D403–459 are detectable in
tissue from the mouse model, while the levels of KLHL3 are unaf-
fected. In vivo, CUL3 auto-ubiquitylation possibly precedes ubiquity-
lation of KLHL3, leading to rapid proteasomal degradation of
CUL3D403–459 leaving KLHL3 untouched. The auto-degradation of
CUL3 is likely to be the major driver for the associated phenotype in
patients. While, some CUL3D403–459 remains in cells, we show that
this remaining protein is unable to ubiquitylate WNK substrates.
Taken together, our data suggest that the disease-associated deletion
of exon 9 from CUL3 is a loss-of-function mutation with respect to
substrate ubiquitylation. Importantly, all PHA2E patients are
heterozygotes, so they retain a functioning copy of CUL3WT. Thus,
the CUL3D403–459 mutation either behaves as a dominant-negative to
inhibit CUL3WT or is haploinsufficient in the context of blood pres-
sure regulation with the single functional copy of CUL3 unable to
sustain the physiological need for WNK ubiquitylation. Our data
support a haploinsufficiency model, as a large proportion of the
mutant protein is removed from the cell by auto-degradation and
in vitro CUL3D403–459 does not inhibit CUL3WT. However, it is possi-
ble that in vivo the remaining CUL3D403–459 may still sequester
KLHL3 from CUL3WT in a dominant-negative fashion, as in cells we
observed increased binding between CUL3D403–459 and KLHL3
(Fig 1H) and the reduced affinity for CAND1 may prevent the
release of KLHL3 from non-functional CUL3D403–459 complexes.
These two possibilities could be addressed in a heterozygous mouse
model carrying a full-length CUL3 deletion; under the haploinsuffi-
ciency model, it should show WNK stabilisation.
The CUL3WT/D403–459 mice have high blood pressure and up-regu-
lated signalling in the context of the WNK kinase pathway, which
parallels the WNK4 (D568E; Yang et al, 2007; Chowdhury et al,
2013) and KLHL3 (R528H; Mori et al, 2013) PHA2 mouse models
previously described. Mechanistically, our data suggest CUL3D403–459
promotes its own degradation, as it has a heightened propensity to
self-ubiquitylate and is less abundant in mouse kidney extract.
Hence, we would predict that PHA2E CUL3WT/D403–459 patients
would similarly have lower overall CUL3 levels. As CUL3 ubiquity-
lates a number of other proteins, it seems remarkable then that
PHA2E patients do not have other phenotypic manifestations.
However, this may not be surprising if considered in the context of
a haploinsufficiency model. BP homoeostasis requires reactive and
precise control of ion fluxes in the distal nephron, especially the
DCT, as changes in intake and output of salt are constantly
balanced. The phosphorylation of the NCC/NKCC ion transporters
by WNK kinases appears to be regulated by two complementary
systems: the regulation of total WNK protein levels by CUL3-KLHL3,
and the level of WNK activation by phosphorylation. Currently, the
sensing mechanisms that lead to WNK phosphorylation or the
degradation of the WNK kinases by CUL3-KLHL3 are largely
unknown. However, sufficient amounts of CUL3 must be available
for signalling-dependent ubiquitylation of the WNK kinases. It is
possible that having only half the amount of functional CUL3 within
kidney cells is not enough for the system to respond rapidly. The
presence in our knock-in mice of WNK4 puncta in vivo also suggests
that DCT cells may deploy secondary protein degradation pathways
to manage excess WNK proteins, such as the autophagy–lysosomal
system. However, the nuclear proximity of the large puncta and the
absence of lysosomal staining or formation of ubiquitylated aggre-
gates suggest that these excess WNK proteins are shunted to
protein quality control compartments such as the aggresome or
◀ Figure 5. WNK4 and SPAK specifically accumulate and form puncta in the distal convoluted tubule of CUL3WT/D403–459 mice.A Representative pseudocoloured maximum-intensity z projections of immunofluorescently stained kidney sections showing the distribution of the WNK/SPAK pathway
components between CUL3WT/D403–459 and CUL3WT mice at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 and KLHL3 are comparable between
genotypes, with significantly higher levels of CUL3 in the proximal convoluted tubule (PCT) compared to the weak staining in distal convoluted tubule (DCT) and thick
ascending limb of the loop of Henle (TAL), while KLHL3 shows higher expression in the DCT/TAL cytosol with staining of the PCT confined to the apical membrane.
Total (t) and phospho (p) NCC Thr44 and SPAK Thr243 show increased apical membrane expression in the parvalbumin (PVALB)-positive early and late (PVALB-
negative) DCT of CUL3WT/D403–459 mice. Unexpectedly, the increased levels of WNK4 and SPAK resulted in the formation of discrete puncta specifically in the DCT of
CUL3WT/D403–459 mice. It is possible that the autophagy–lysosomal system may attempt to compensate and degrade these excess proteins although the WNK4 puncta
do not colocalise with the lysosomal marker LAMP1. Scale bar, 20 lm.
B Representative immunohistochemical staining of KLHL3 and CUL3 in human kidney sections (n = 6). KLHL3 shows preferential DCT/TAL cytosolic staining similar to
the mouse despite no evidence of PCT apical staining as seen in (A). CUL3 exhibits preferential basolateral cytosolic staining of the PCT with similarly low levels of
diffuse staining in the DCT/TAL to that of the mouse. Scale bar, 100 lm.
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juxta-nuclear quality control compartment (JUNQ) in an attempt to
compensate for loss of proteasomal degradation (Lamark &
Johansen, 2012; Wolff et al, 2014). Hence, while other CUL3
substrates may be unaffected in the CUL3WT/D403–459 mice, the rapid
and signal-dependent switching of WNK ubiquitylation may be
executed abnormally in these mice and PHA2E patients.
Mutations in CUL3, KLHL3, WNK1 and WNK4 are known to
cause FHHt with constitutive activation of the NCC co-transporter
(Boyden et al, 2012; Osawa et al, 2013; Tsuji et al, 2013; Alessi
et al, 2014; Glover et al, 2014). What has been less clear is why
the mutation of CUL3 has resulted in a more severe form of FHHt
(PHA2E). Our unexpected discovery of a vascular phenotype in
the CUL3WT/D403–459 mice leads us to speculate that their hyperten-
sion may not be driven by salt retention in the DCT alone. It is
possible that part of their hypertension originates from an
increased contractile state in their vasculature tree. If a similar
phenomenon occurs in PHA2E, this may explain the early onset
and severity of the blood pressure that occurs in these patients.
The CUL3WT/D403–459 mice have an altered aortic pulse waveform
and slowed diastolic relaxation that is consistent with stiffening of
their arterial tree. These changes have been reported before in
humans with hypertension (Kaess et al, 2012), but not previously
in a hypertensive mouse model. It is also worth noting that
augmentation of the aortic pressure wave is often not detected by
brachial cuff BP measurements, so it could have gone unnoticed in
the routine clinical assessment of PHA2E patients. The increase in
pMYPT1 in the aortae from the CUL3WT/D403–459 mice and the
increase in their in vivo pressor responses to phenylephrine and
angiotensin II further suggest that the altered contractile state
could be a primary phenomenon rather than simply a secondary
response to hypertension. If this is the case, the contraction could
occur by at least two distinct pathways. Firstly, the WNK1/WNK3/
SPAK/OSR1 pathway is thought to be important for regulating
vascular tone by controlling the phosphorylation state of the
NKCC1 co-transporter and hence the membrane potential of vascu-
lar smooth muscle (VSM) cells (Yang et al, 2010; Bergaya et al,
2011; Zeniya et al, 2013). So if either WNK1 or WNK3 accumu-
lates in the vessel wall of the CUL3WT/D403–459 mice, the contractile
tone would be expected to rise through depolarisation of VSM and
increased calcium entry. Alternatively, the mutant Cullin-3 protein
may directly affect the phosphorylation state of myosin light chain
by regulating RhoA/RhoA kinase (ROCK) levels (Ibeawuchi et al,
2015). RhoA protein levels in the VSM are thought to be regulated
by CUL3 in complex with the substrate adaptor RhoBTB1 (Pelham
et al, 2012). If these pathways are operational in PHA2E, then they
suggest that treatment with a thiazide diuretic or dietary sodium
restriction, while effective in reversing the electrolyte disturbances,
may be less effective in reversing any central aortic pressure
changes in PHA2E. If WNK/SPAK/OSR1 is the predominant path-
way causing disease, a loop diuretic such as bumetanide may be
more effective than a thiazide, while for the RhoA/ROCK pathway
a direct arterial vasodilator or a specific ROCK inhibitor (Liao et al,
2007) may be the more appropriate drug of choice. Central aortic
pressure elevation is now widely accepted to be an important and
independent cardiovascular risk factor (Liao & Farmer, 2014), so if
it is elevated in patients with PHA2E, it will be important to show
that it is normalised by appropriate pharmacotherapy.
Materials and Methods
All plasmids, antibodies and recombinant proteins that we have
generated for this study are available on request from the MRC-PPU
reagents website (http://mrcppureagents.dundee.ac.uk/).
Plasmids and protein purification
The following plasmids and/or protein purifications have been
described elsewhere in Ohta et al (2013): KLHL3 (DU23218), DAC-
TEV-CUL3-RBX1 (DU23291), His-UBE1 (DU32888) and His-TEV-
UBE2D3 (DU15703); and in Kelsall et al (2013): Nedd8 (DU20689),
UBE2M (DU15804) and APPBP1/UBA3 heterodimer (Nedd8 activating
E1) (DU21784).
DAC-TEV-CUL3D403–459-RBX1 (DU23292) was cloned in a
comparable way to DAC-TEV-CUL3WT-RBX1 (DU23291). Specifi-
cally, the pFastBac Dual DAC-TEV expression system was created
by subcloning a BglII-BamHI-flanked PCR product encoding the
full-length DAC-tag followed by a TEV protease site into a
◀ Figure 6. Increased arterial stiffness contributes towards the hypertension of CUL3WT/D403–459 mice.A Continuous blood pressure measurements were taken in mice under general anaesthesia with thermostatically controlled body temperature, right carotid artery
pressure transducer catheterisation and ECG Lead II heart rate monitoring. CUL3WT/D403–459 mice have elevated systolic (SBP) (***P = 1 × 1012) and diastolic (DBP)
blood pressure (***P = 8.5 × 108), although they also present with 7% lower heart rates (*P = 0.0485) when compared to CUL3WT mice. Two-tailed unpaired
Student’s t-test; data are mean  SEM.
B Pulse waveform analysis of blood pressure traces obtained in (A) reveals that CUL3WT/D403–459 mice have an increased pulse pressure (PP) [SBP – DBP]
(***P = 2.1 × 1010), augmentation pressure (AP) [SBP – anacrotic notch (AN) pressure] (***P = 3.5 × 106), dicrotic notch (DN) pressure (***P = 4.7 × 1013) and
mean arterial pressure (MAP) [1/3 × SBP + 2/3 × DBP] (***P = 1.3 × 109). This hypertensive phenotype is in part due to changes in vascular contractility in
CUL3WT/D403–459 mice as evidenced by their higher augmentation index (AIx) [AP/PP] (**P = 0.0096), a marker of arterial stiffness, and is further supported by an
increase in their diastolic pressure decay time constant (sbourgeois) [1/slope of diastolic pressure decay; measured 30 ms after DN and 20 ms before end DBP]
(**P = 0.0083), a surrogate marker of increased vascular resistance. Two-tailed unpaired Student’s t-test; data are mean  SEM
C In vivo dose–responses to phenylephrine and angiotensin II. After baseline measurements were obtained from mice in (A), the right external jugular vein was
cannulated for administration of bolus doses of vasopressors in increasing half-log steps. Dose–response curves were generated and data analysed using a logistical
function to determine the estimated dose producing half-maximal response (ED50) and maximum response (Emax). The fitted Emax for phenylephrine was increased in
CUL3WT/D403–459 versus CUL3WT (183.9  2.5 versus 164.9  1.4 mmHg) (***P = 1 × 106) indicating an increased vasoconstrictor response to adrenergic stimulation
elevating systolic blood pressure substantially above the CUL3WT maximum. Similarly, the fitted Emax for angiotensin II stimulation was higher in CUL3
WT/D403–459
versus CUL3WT (155.5  1.8 versus 138.3  2.2 mmHg) (***P = 1.7 × 106). However, there was no change between CUL3WT/D403–459 versus CUL3WT sensitivity (as
measured by ED50) to phenylephrine (36.6  5.1 versus 31.4  2.8 lg/kg bw) (P = 0.3778) or angiotensin II (0.77  0.16 versus 0.93  0.13 lg/kg bw) (P = 0.4401).
Two-tailed unpaired Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
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pFastBacTM Dual (Life Technologies, UK). Human Cullin-3 (D403–459;
GenBank NM_003590.4) was codon-optimised for expression in
insect cells and custom synthesised (GenScript USA Inc.) before
being subcloned downstream of the DAC-tag in cassette two of this
vector. Human RBX1 (GenBank NM_014248.2) was amplified from
an EST IMAGE clone 3138751 and subcloned into cassette one (un-
tagged). Human CAND1 (GenBank NM_018448.3) was amplified as
a Not1 flanked ORF from EST IMAGE clone 5265409 and
subcloned into pGEX6P-2 (GE Healthcare LifeSciences UK) for
bacterial expression with an N-terminal GST tag. All PCRs were
carried out using KOD Hot Start DNA Polymerase (Merck Millipore,
Germany). All full-length products or fragments were cloned into
pSc-B (Agilent) and sequenced in full prior to further subcloning or
manipulation. DNA sequencing was performed by the Sequencing
Service at the College of Life Sciences, University of Dundee
(www.dnaseq.co.uk).
Human recombinant CUL3D403–459-RBX1 or CUL3WT-RBX1 was
expressed in a multibac vector with a Dac-TEV-fusion tag on the
CUL3 and untagged RBX1 (Lee et al, 2012). Proteins were
expressed in the baculovirus system in Sf21 cells cultured in
Insect-Protein-free Insect Cell Medium (Lonza). The fusion protein
was captured from the lysate by incubation with ampicillin-
sepharose. After washing, the protein was recovered from the solid
phase by incubation with C-terminally His-tagged TEV protease
(10 lg per 1 mg substrate). The protease and any free Dac-tag
were removed with Ni-agarose and ampicillin–sepharose. The
protein was then concentrated and further purified by size-
exclusion chromatography (SEC) in 50 mM HEPES pH 7.5,
150 mM NaCl and 10% glycerol.
Human recombinant CAND1 was expressed as an N-terminally
GST-tagged fusion protein in BL21 cells. Expression was induced
with 50 lM IPTG at 15°C for 16 h. Following cell lysis, GST-CAND1
was captured on glutathione resin, washed and then eluted from the
resin with 10 mM reduced glutathione in 50 mM HEPES pH 7.5,
150 mM NaCl, 10% glycerol (w/v) and 1 mM DTT. The protein was
then dialysed to remove glutathione.
Nedd8 was expressed as an untagged protein in BL21 cells, and
following induction with 1 mM IPTG at 16°C, cells were lysed and
frozen. Upon thawing, benzonase and 2 mM Mg(C2H3O2)2 were
added and cells were disrupted by sonication. Insoluble material
was pelleted, and this pellet was resuspended in 50 mM Tris pH 7.5
and 150 mM NaCl and washed thrice. To extract Nedd8, the pellet
was resuspended in 8 M urea and mixed overnight. Following
clarification by centrifugation the supernatant was diluted fourfold
with MQ water and dialysed thrice to remove urea and enable
Nedd8 refolding. Contaminants were removed by depletion using a
Q-sepharose column. The Nedd8 was concentrated prior to a final
purification by SEC in 20 mM HEPES pH 7.5, 150 mM NaCl and
0.03% Brij 35.
Antibodies
The following antibodies were raised in sheep and affinity-puri-
fied on the appropriate antigen by the Division of Signal Trans-
duction Therapy Unit at the University of Dundee: WNK1-total
antibody (residues 2,360–2,382 of human WNK1, S62B), WNK4
N-terminal antibody (residues 1–14 of mouse WNK4, S726D),
SPAK-mouse N-terminal antibody (2–76 of mouse SPAK, S668D),
SPAK-mouse C-terminal antibody (424–556 of mouse SPAK,
S669D), SPAK/OSR1 (T-loop) phospho-Thr233/Thr185 antibody
(226–238 of human SPAK or residues 178–190 of human OSR1,
TRNKVRKpTFVGTP, S204C), SPAK phospho-Thr233 antibody
(226–238 of human SPAK, TRNKVRKpTFVGTP, S668B and
S668D), NKCC1-total antibody (residues 1–260 of shark NKCC1,
S841B), NCC phospho-Thr60 antibody (residues 54–66 of human
NCC phosphorylated at Thr60, RTFGYNpTIDVVPT, S995B), NCC
phospho-Thr44 antibody (residues 38–52 of mouse NCC phospho-
rylated at Thr44, SQPSHLTpHGSTLYMRRR, S242C) and KLHL3
N-terminal mouse (1–21 of mouse KLHL3, S740D). The anti-ERK1/2
antibody (9102) was purchased from Cell Signaling Technology.
The anti-FLAG antibody (F1804), anti-b-actin antibody and anti-
His antibody were purchased from Sigma-Aldrich. The rabbit anti-
human CUL3 antibody was a kind gift from Izabela Sumara at
the IGBMC, Strasbourg (Sumara et al, 2007). The following
commercial rabbit anti-human antibodies were obtained and used
for immunodetection: KLHL3 antibody (HPA051291) from Atlas
Antibodies; KLHL3 (AB196776) (~14% immunogen peptide
homology with KLHL2), NCC-total [SLC12A3] (AB95302) and
LAMP1 (AB24170) from Abcam; and PV25 (PVALB) from Swant.
The goat anti-GFP (AB5450) and the mouse monoclonal anti-
ubiquitin (AB7254) were purchased from Abcam. The MYPT1
phospho-Thr696 mouse monoclonal antibody (MAB0001) was
obtained from Abnova. Secondary antibodies coupled to horse-
radish peroxidase used for immunoblotting were obtained from
◀ Figure 7. CUL3 and KLHL3 are present in mouse and human aorta, and CUL3WT/D403–459 mice undergo aortic vascular remodelling.A Western blot of tunica media-intima thoracic aorta lysates from mice culled after a minimum 4-h fast. Following exsanguination after surgery, mouse tissues were
rapidly harvested and the tunica adventitia removed before storage, and later, the samples were homogenised, clarified and quantified prior to SDS–PAGE. Western
blot analysis confirmed the expression of KLHL3 and CUL3. Similar to the kidney, the aorta of CUL3WT/D403–459 showed slightly lower levels of CUL3 compared to
CUL3WT without any change in KLHL3 levels.
B Fresh frozen thoracic aorta tissues from donor cadavers were homogenised, clarified and quantified prior to SDS–PAGE. Western blot analysis confirmed the
expression of KLHL3 and CUL3 in normal healthy human aorta.
C Representative maximum-intensity z projections of immunofluorescently stained thoracic aorta sections showing the distribution of CUL3 and KLHL3 between
CUL3WT/D403–459 and CUL3WT mice at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 and KLHL3 localisation is comparable between genotypes. The
highest levels were detected in the vascular smooth muscle cells and endothelium, with a minimal expression in the perivascular adipose tissue of the adventitia.
Scale bar, 50 lm.
D Representative immunohistochemical staining of KLHL3 and CUL3 in human thoracic aorta sections (n = 6). Similar to the mouse staining seen in (C), vascular
smooth muscle cells in the tunica media of the aortic wall are positive for KLHL3 and CUL3. Scale bar, 50 lm.
E Morphometric analysis of thoracic aortae reveals vascular remodelling in CUL3WT/D403–459 mice. There is an increase of ~21% in the vessel wall intima-media
thickness (demarcated by arrows) of CUL3WT/D403–459 compared to CUL3WT mice (***P = 0.0003). However, there is no change in the number of elastin laminae
(P = 0.1458) and therefore no increase in the number of medial muscle layers between genotypes. Two-tailed unpaired Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
ª 2015 The Authors EMBO Molecular Medicine
Frances-Rose Schumacher et al Cullin-3 and defective WNK ubiquitylation in PHA2E EMBO Molecular Medicine
15
Published online: August 18, 2015 
Pierce. Secondary antibodies conjugated to fluorochromes for
LiCor Odyssey Western blot scanning were obtained from Licor
(www.licor.com) and Life Technologies. Fluorochrome-conjugated
secondary antibodies for immunofluorescent confocal microscopy
were obtained from Life Technologies and Abcam.
In vitro assays
Ubiquitin E2 discharge assays were performed based on the
method described (Plechanovova´ et al, 2011). Firstly, His-UBE2D2
(150 lM) was incubated in the presence of 2 mM ATP, 5 mM
MgCl2, 200 lM ubiquitin and 0.25 lM UBE1 in 50 mM HEPES pH
7.5, 150 mM NaCl, 10% glycerol and 1 mM DTT at 16°C for
15 min. To stop the reaction, we depleted ATP by incubating the
charging mixture with apyrase (4.5 U/ml; New England Biolabs)
at 16°C for 10 min. To this, 1 lM E3 was added and discharge
reactions were then allowed to proceed for the time indicated in
the figure, at 30°C. Reactions were stopped by the addition of
non-reducing SDS–Laemmli sample buffer. 16% bis-acrylamide
non-reducing SDS–PAGE, followed by immunodetection with anti-
His antibody, allowed visualisation of ubiquitin discharge. E3
ubiquitin-ligase activity assays were based on those described
previously in Ohta et al (2013). When used as a substrate in
assays, full-length WNK kinases were purified from HEK-293 cells,
and either 5 ll of immunoprecipitated endogenous WNK1 protein
derived from 0.5 mg of HEK-293 cells or 5 ll of immunoprecipi-
tated over-expressed FLAG-WNK4 from 0.05 mg of HEK-293 cells
was used for each assay reaction. Ubiquitylation assays typically
contained 20 mM HEPES/HCl (pH 7.5), 150 mM NaCl, 2 M DTT,
10% (w/v) glycerol, 8 lM CUL3-RBX1 complex (WT or mutant),
7 lM KLHL3, 7 lM UBE1, 60 lM UBE2D3 and 3,000 lM ubiqui-
tin. The concentrations of some components were altered on occa-
sion (e.g. Fig 3B) to best illustrate a given point. Reactions were
initiated by adding ATP and MgCl2 to a final concentration of
1 mM, and samples were incubated for the times indicated at
30°C. Reactions were stopped by the addition of SDS sample
buffer, and samples were analysed after SDS–PAGE followed by
immunoblotting or Coomassie blue gel staining. For the N8-ligase
activity assays, 1 lM E3 was incubated at 30°C with 68 lM
Nedd8, 8 lM UBE2M and 0.2 lM NAE in the presence of
0.15 mM ATP, 1.5 mM MgCl2 50 mM HEPES pH 7.5, 150 mM
NaCl and 20% (w/v) glycerol for the time indicated. Reactions
were stopped by the addition of SDS sample buffer, and samples
were analysed following SDS–PAGE separation and Coomassie
blue staining.
In vitro protein interaction pull downs
For KLHL3-CUL3, anti-KLHL3 resin was made by covalently coupling
anti-KLHL3 antibody (S377D) to Protein G sepharose utilising
dimethyl pimelimidate. Anti-KLHL3 resin, or control resin (prepared
in the absence of any antibody), was incubated with saturating
amounts of purified KLHL3 and washed thrice, resulting in KLHL3
resin. This resin was then incubated with CUL3WT or CUL3D403–459 at
4°C for 1 h, before being washed thrice with PBS 0.02% Tween-20.
For CAND1-CUL3, purified GST-CAND1 or GST was incubated in
excess with resin at 4°C resulting in GSH-resin-GST or GSH-GST-
CAND1 resin. Each resin was then incubated with purified CUL3WT
or CUL3D403–459 for 1 h at 4°C before being washed once with PBS
0.02% Tween-20 and then twice with PBS in the absence of deter-
gent. Following washing, volumes were reduced to a minimum and
proteins were eluted from the resin by the addition of SDS sample
buffer, prior to analysis by SDS–PAGE and immunoblotting.
Cell culture
HEK (human embryonic kidney)-293 cells were cultured in 14-cm
dishes in DMEM (Dulbecco’s modified Eagle’s medium; Life Tech-
nologies) supplemented with 10% (v/v) foetal bovine serum, 2 mM
L-glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin.
Protein expression was induced for 24 h with 1 lg/ml tetracycline
(Life Technologies). To obtain endogenous WNK1 for activity
assays, we followed the immunoprecipitation protocol described in
Ohta et al (2013). To obtain wild-type FLAG-WNK4, we utilised the
cell lines from Schumacher et al (2014) and Ohta et al (2013).
When FLAG-WNK4 was to be used for in vitro ubiquitylation
assays, a 14-cm plate of confluent cells was lysed in 0.5 ml ice-cold
mammalian lysis buffer A (mammalian lysis buffer A: 50 mM
Tris/HCl (pH 7.5), 0.15 M NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM
Na3VO4, 50 mM NaF, 5 mM Na4P2O7, 0.27 M sucrose, 1% (w/v)
Nonidet P-40, 1 mM benzamidine, 0.1 mM PMSF, 0.1% 2-mercap-
toethanol, and Roche protease inhibitor mix (1 tablet in 50 ml) for
M2 affinity purification). Lysates were clarified by centrifugation,
and to this, 10 ll M2 resin per 100 ll lysate was added. Incubation
of the resin with the cellular lysate for 1 h at 4°C was followed by
two washes with mammalian lysis buffer A, and two further washes
with 1× PBS to give a pure M2-Flag-WNK4 slurry. For interaction
studies with FLAG-CUL3WT and FLAG-CUL3D403–459, the same
method was followed as above, with an alternative mammalian lysis
buffer B (50 mM HEPES/KOH pH 7.2, 5 mM Mg(C2H3O2)2, 70 mM
KC2H3O2, 0.2% (w/v) Triton X-100, 10% (w/v) glycerol, 0.2 mM
EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM Na4P2O7 and Roche
protease inhibitor mix (1 tablet in 50 ml)). When it was desirable to
prevent deneddylation, buffers were supplemented with 50 lM
1,10-phenanthrolin.
Mass spectrometry analysis
Prior to SDS–PAGE, samples were reduced and alkylated in the
following way. Reactions were stopped at the time shown and incu-
bated at 95°C in 1× LDS (Invitrogen) 5 mM DTT for 1 min. Alkyla-
tion occurred at room temperature for 30 min by the addition of
20 mM iodoacetamide (20 mM) to the samples. To quench the reac-
tion, DTT was added to a final concentration of 20 mM, and the
sample was then processed on precast 4–12% gradient gel (Invitro-
gen). Gel pieces were excised as shown by the boxed areas in the fig-
ure and in gel digestion of the proteins with 5 lg/ml trypsin and
subsequent analysis. Mass spectrometric analysis was performed by
LC-MS-MS on a linear ion trap–orbitrap hybrid mass spectrometer
(Orbitrap-VelosPro; Thermo) coupled to a U3000 RSLC HPLC
(Thermo). Peptides were trapped on a NanoViper trap column,
2 cm × 100 mm C18 5 mm 100 A˚ (Thermo, 164564) and then sepa-
rated on a 15-cm Thermo EasySpray column (ES800) equilibrated
with a flow of 300 nl/min of 3% solvent B [solvent A: 2% acetoni-
trile, 0.1% formic acid and 3% DMSO in H2O; solvent B: 80%
acetonitrile, 0.08% formic acid and 3% DMSO in H2O]. The elution
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gradient was as follows: time (min): solvent B (%): 0:3, 5:3, 45:35,
47:99, 52:99, 55:3 and 60:3. The instrument was operated with the
“lock mass” option to improve the mass accuracy of precursor ions,
and data were acquired in the data-dependent mode, automatically
switching between MS and MS-MS acquisition. Full-scan spectra
(m/z 400–1,600) were acquired in the orbitrap with resolution
R = 60,000 at m/z 400 (after accumulation to an FTMS Full AGC
Target, 1,000,000; FTMS MSn AGC Target, 50,000). The 20 most
intense ions, above a specified minimum signal threshold (2,000),
based upon a low-resolution (R = 15,000) preview of the survey
scan, were fragmented by collision-induced dissociation and
recorded in the linear ion trap (Full AGC Target, 30,000; MSn AGC
Target, 5,000). Data files were analysed by Proteome Discoverer 1.4-
SP1 (Thermo), using Mascot 2.4.1 (www.matrixscience.com), and
searching an in-house database containing the relevant sequences.
Scaffold (www.ProteomeSoftware.com) was also used to examine
the Mascot result files. Allowance was made for the following fixed,
Carbamidomethyl (C), and variable modifications, Oxidation (M),
Dioxidation (M), GlyGly (K), LeuArgGlyGly (K) and Phospho (ST).
Error tolerances were 10 ppm for MS1 and 0.6 Da for MS2.
Generation and genotyping of WT and CUL3D403–459 mice
Standard housing conditions were used to maintain the mice.
Taconic Artemis generated the CUL3D403–459 mice on a C57BL/6N
background, which were backcrossed onto C57BL/6J to maintain
the colony. All experiments were performed using littermates that
were backcrossed at least once onto C57BL/6J. Genomic DNA from
ear biopsies was isolated and used to genotype all mice in the study.
Genotyping by PCR utilising primer 1: AAACTTACCCACTTGTT
TGCC, and primer 2: AGACATCTCAGGTTACTATGGGC detected
the presence of the CUL3WT (683 bp) or CUL3D403–459 (395 bp)
allele. Studies were conducted on groups of approximately equal
ratios of male-to-female mice with the exception of in vivo cardio-
vascular phenotyping in which a 1:2 ratio of male-to-female mice
was used. All animal studies and breeding were approved by the
University of Dundee ethical committee and performed under a UK
Home Office-approved licence.
Mouse kidney and testes lysates
Mouse tissues were rapidly harvested and either snap-frozen in
liquid nitrogen and stored at 80°C or incubated in 1 ml RNAlater
solution (Sigma-Aldrich) at 4°C for 16–30 h before being removed
from this buffer, patted dry with clean tissue and then stored dry at
80°C. Lysates were prepared by homogenising tissue on ice using
a Polytron PT1200C homogenizer (Kinematica) in 2 ml ice-cold
mammalian lysis buffer and then clarified by centrifugation at
18,000 g for 30 min. The clarified supernatant was then quantified
and used immediately. Any excess sample was snap-frozen in
liquid nitrogen in single-use aliquots for use as required.
The lysates to be used for immunoprecipitation were prepared in
the same way, with the following exceptions, all designed to
promote deneddylation of the cullin proteins. Detergent was not
included in the lysis buffer. Following homogenisation, samples
were incubated on ice for 4 h. Following clarification by centrifuga-
tion at 18,000 g for 30 min, samples were aliquoted into fractions
and either frozen in liquid nitrogen and stored at 80°C or used
immediately. Clarified supernatant was incubated at room tempera-
ture for 1 h to enable further deneddylation, and samples were then
cooled on ice and centrifuged a second time to ensure any precipi-
tate was removed. Anti-CUL3 antibody (S067D) cross-linked (DMP)
to Protein G agarose was mixed with saturating amount of lysate
and incubated rotating overnight at 4°C. The next morning, the
agarose beads were washed thrice with mammalian lysis buffer B
and twice with 1× PBS. Proteins were eluted from beads by SDS
sample buffer addition and boiling at 95°C for 10 min prior to
centrifugation and SDS–PAGE and immunodetection.
Immunoblotting
Lysates or protein mixes were boiled at 95°C with 1× SDS–Laemmli
sample buffer, for 5 min before being subject to SDS–PAGE (8 or
10% Tris–glycine gel, or 4–10% gradient gels (Life Technologies) or
self-prepared 16% bis-acrylamide). Gels were transferred to nitrocel-
lulose membrane using the standard wet transfer method (15%
MeOH Towbin transfer buffer). Following blocking of the
membranes (TBST 5% (w/v) dried skimmed milk), they were then
incubated overnight at 4°C with the primary antibody indicated. All
DSTT-produced sheep antibodies were used at 2 lg/ml, and phos-
pho-specific antibodies included the addition of 10 lg/ml of the
dephospho-peptide used to raise the antibody. Commercial antibod-
ies were diluted 1 in 1,000. Membranes were then washed in TBST
five times and incubated with the appropriate secondary HRP anti-
body at room temperature at 1:5,000 dilution. Membranes were
subsequently washed five times, and the HRP signal was detected
using chemiluminescence reagent (Pierce). Immunoblots were
developed using an automatic film processor (SRX-101; Konica
Minolta Medical).
CUL3 structural docking
Cullin-3 was modelled using Phyre2 server (Kelley & Sternberg,
2009) using human CUL3D403–459 as the sequence input and Cullin-1
chosen for the docking model (Q13616, PDB:1LDK; Zheng et al,
2002). A coil was predicted in place of the missing structural
elements. UBE2D~UB was docked to RBX1 using PDB: 4AP4. Images
were modified and made in UCSF Chimera (Pettersen et al, 2004;
http://www.cgl.ucsf.edu/chimera).
Immunoprecipitation (mouse tissue and cell extracts)
Lysates of cellular preparations (buffer B) from FLAG-tagged
CUL3 were mixed with M2 resin in the presence of 50 lM 1,10-
phenanthrolin to prevent deneddylation and were incubated rotating
at 4°C for 1 h. Resins were washed twice with mammalian buffer B
and twice with 1× PBS, the volume was then reduced to ~15 ll, and
following the addition of SDS gel sample buffer to 1×, samples were
boiled and the entire sample was loaded to allow analysis by SDS–
PAGE and immunodetection with the antibodies indicated.
Human and mouse aorta sample preparation
Human aortic tissues were collected from donors through trans-
plant coordinators at Addenbrooke’s Hospital, Cambridge. All
samples were handled in accordance with the policies and
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procedures of the Human Tissue Act and with the approval of the
Local and Regional Ethics Committees. Mouse tissues were rapidly
harvested, perivascular fat and residual blood were removed, and
the samples were incubated in 1 ml RNAlater solution at 4°C for
16–30 h before being removed from this buffer and stored dry at
80°C. Frozen aortic tissues were homogenised using TissueLyser
LT (Qiagen #85600), and protein lysates were extracted in NE-PER
(Life Technologies #78833) lysis buffers containing protease and
phosphatase inhibitors (Roche #11836170001 and #04906845001).
All steps were carried out at 4°C. Protein concentrations were
determined with the PierceTM BCA protein assay (Life Technologies
#23225).
Human and mouse aorta immunoblotting
A total of 10 lg of aortic protein lysates was separated by SDS–
PAGE. Prior to loading, samples were heated at 70°C for 10 min in
1× LDS sample buffer and 1× reducing agent (Life Technologies
#B0007 and # B0009) to a total volume of 20 ll/well. Samples and
5 ll of Precision Plus molecular weight ladder (Biorad #161-0374)
were then loaded onto a Bolt 4–12% Bis–Tris Plus Gel (Novex
#BG04125BOX) and run at 165 V in 1× MES running buffer
(Novex #B0001), for 35 min or until the dye front reached the
end of the gel. Resolved proteins were then transferred to 0.22 lM
nitrocellulose membrane (Life Technologies #IB23001) using the
iblot2 (Life Technologies) at 20 V for 7 min. Antibodies were incu-
bated in 5% milk. Membranes were incubated in 5% in milk or
BSA in TBS for 1 h at room temperature. Primary antibodies were
incubated overnight at 4°C in 5% milk or BSA in TBS–Tween
(0.1% v/v Tween) and then washed 6× in TBS–Tween. Secondary
antibodies were incubated in TBS–Tween for 1 h at room tempera-
ture in the dark and then washed 6× in TBS–Tween. Membranes
were imaged and integrated intensity values quantified (bands
were normalised against b-actin) using the LiCor Odyssey system
(www.licor.com).
Sample preparation and immunostaining for imaging
Formal-fixed, paraffin-embedded human tissue sections were
obtained from the Cambridge Human Research Tissue Bank.
Harvested mouse tissues were immersion-fixed in fresh 4% w/v
formaldehyde–PBS pH 6.9 for 16 h at 37°C and washed 3× in PBS
and stored at 4°C until paraffin embedding. Five-micrometre
sections were deparaffinised in Histoclear (National Diagnostics)
and rehydrated in graded methanol steps. An antigen retrieval step
was performed with R-Universal buffer in the 2100 antigen retriever
for a single heat–pressure cycle (Aptum Biologics). Sections were
permeabilised with 0.05% v/v Triton X-100–PBS for 20 min and
blocked for 1 h at 37°C with 2% v/v donkey serum in 0.05% v/v
Triton X-100–PBS. Primary antibodies were incubated overnight for
16 h at 4°C at the following concentrations diluted in 1% v/v donkey
serum in 0.05% v/v Triton X-100–PBS: 2 lg/ml for pNCC T44, tNCC,
CUL3 (Sumara et al, 2007); 4 lg/ml for KLHL3 N-terminal,
WNK4 N-terminal, SPAK C-terminal and pSPAK T233 (to detect
mouse pSPAK T243); and 1 lg/ml for LAMP1, 1:500 for ubiquitin
and 1:2,000 for PVALB. Phospho-specific antibodies included the
addition of 10 lg/ml of the non-phospho form of the peptide used to
raise the antibody per 2 lg/ml of antibody used. Slides were then
washed for 20 min in 0.05% v/v Triton X-100–PBS and incubated in
secondary antibody for 1 h at 37°C. Pre-absorbed donkey IgG-conju-
gated Alexa Fluor 488, 568, 633 and 647 secondary antibodies (Life
Technologies/Abcam) were used at 1:200 dilution in 1% v/v
donkey serum in 0.05% v/v Triton X-100–PBS for immunofluores-
cent labelling. Slides were washed as described above, mounted
using Prolong Gold Antifade (P36930; Life Technologies) and
shielded from light. Human IHC DAB staining was performed with
ImmPRESS Reagent peroxidase universal anti-mouse/rabbit IgG
(MP-7500, Vector) kit, after which slides were then dehydrated
through graded methanol steps and mounted with DPX.
Image acquisition and processing
Immunofluorescence images were acquired on the Leica TCS SP2
laser scanning confocal microscope with 488-, 543- and 633-nm
laser lines mounted on an upright Leica DM RXA fluorescence
microscope using a HCX PL APO 63×/1.40NA oil immersion objec-
tive. Acquisition parameters were as follows: 12-bit, 1,024 × 1,024
pixels, 2.6× digital zoom, 800 Hz scan speed, 4-line Kalman filter-
ing, sequential (by line) channel imaging, and 10-slice z-stack of
5 lm. Immunohistochemically stained specimens were imaged in
brightfield on an Olympus BX51 upright epifluorescent microscope
using a UPLANFL 20×/0.5NA dry objective with the Infinity3
(Lumenera) CCD set to 1,936 × 1,456 pixels.
In FIJI image analysis software (http://fiji.sc/Fiji), fluorescent z-
stacks underwent background subtraction (1,000-pixel-radius rolling
ball, no smoothing) and maximum-intensity z-projection. Brightness
and contrast were adjusted by linear histogram stretching to
enhance visibility. Any images to be compared to one another were
processed in parallel. Similarly, brightfield images underwent linear
histogram stretching to increase visibility uniformly across the
image.
Morphometric analysis
Body weight was regularly measured two times per week through-
out the study to determine differences in mass in age-matched mice.
Body length was measured using photographs of mice post-mortem
with a reference scale. Full body length was determined as well
as tail:body length ratio. Three 5-lm sections of thoracic aorta
were taken at upper (heart), mid and lower (near diaphragm)
segments per mouse. These were deparaffinised, rehydrated and
stained with haematoxylin and eosin, and then dehydrated and
mounted. Each section was imaged under brightfield illumination
and epifluorescent imaging of autofluorescent elastin laminae with
a GFP filter set. Using FIJI image analysis software, macros were
scripted to draw eight lines at ~22.5° to one another that intersect
the aortic ring at a total of 16 points. At the point of intersection
on the outer circumference, the distance from the external lamina
to the inner lumen was measured. The average of the three rings
(max of 16 points per ring, with points excluded if they fell on
an arterial branching point or incomplete portion of a ring) was
used to calculate the average thoracic aorta intima-media wall
thickness. The above step was repeated to count the average
number of elastic laminae in the thoracic aorta of each mouse.
Data collection and analysis were carried out in a blinded
fashion throughout.
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In vivo cardiovascular physiology
Animals were anaesthetised with isoflurane on 100% O2 (induction:
3%, maintenance: 1.75%) and placed on a self-regulating rectal
probe-coupled heat mat (TC-1000; CWE) to maintain a body temper-
ature of 37°C. Heart rate was measured by the R-R wave interval
from ECG Lead II using an animal bio amp (FE136; AD Instruments)
with needle electrodes inserted into fore and hind limbs (MLA1213;
AD Instruments). The right carotid artery was catheterised with a 1F
Mikro-Tip pressure transducer (SPR-1000; Millar) connected to a
bridge amp (FE221; AD Instruments) and powerlab system
(PL3504/P; AD Instruments). When the animals had stabilised,
measurements were taken at 2,000 samples/s using LabChart ver-
sion 7/8 Pro (AD Instruments) to record ECG and blood pressure
pulse waveforms. In vivo dose–responses to vasopressor agents
were taken after baseline blood pressure traces were obtained from
mice. The right external jugular vein was cannulated for administra-
tion of bolus doses in increasing half-log steps of lg/kg body weight
(bw); initially, phenylephrine was administered, and after washout
and return to baseline, angiotensin II was administered in a similar
fashion. Each dose concentration was made up as a half-log serial
dilution in sterile 0.9% w/v saline and administered at a volume of
0.2 ml/kg.bw with an accompanying 20 ll 0.9% w/v saline cannula
flush between doses.
Data processing and analysis were performed in LabChart 8
Pro. Using the blood pressure add-on, systolic, diastolic and
dicrotic notch blood pressures were automatically detected per
beat (beats with respiratory-induced artefact were gated out of the
analysis using the beats classifier). Mean arterial pressure was
calculated as (1/3 peak systolic pressure + 2/3 end diastolic pres-
sure) and pulse pressure as (peak systolic pressure – end diastolic
pressure). A macro was scripted to detect the anacrotic notch, by
using the third zero value crossing the fourth derivative of the
blood pressure, as described in Kelly et al (1989). The augmenta-
tion pressure was calculated as (peak systolic pressure – anacrotic
notch pressure) and augmentation index as (augmentation pres-
sure/pulse pressure). A macro was scripted to measure the slope
of the diastolic pressure decay, 30 ms after the dicrotic notch and
20 ms before the end diastolic pressure (to avoid perturbations
caused by aortic valve opening/closing). The reciprocal of this
slope (ignoring the sign and calculated from the 20% trimmed
mean values) was used to determine the time decay constant of
the diastolic pressure decay which correlates with vascular resis-
tance, as described previously (Bourgeois et al, 1974). Dose–
response curves were generated and data analysed (GraphPad
Prism 5 and LabChart 8 Pro) using a 4-parameter logistical func-
tion to determine the estimated dose producing half-maximal
response (ED50) and maximum response (Emax). Data collection
and analysis were carried out in a blinded fashion throughout.
Sample sizes for the mouse work were decided based on previous
experience in a related mouse model (Rafiqi et al, 2010). When
groups of animals were being compared, procedures were
performed on animals selected at random from the groups.
Blood and urine analytes
To reduce variability introduced by dietary potassium ingestion,
animals were fasted for a minimum of 4 h before being anaes-
thetised with isoflurane on 100% O2 (induction: 3%, maintenance:
1.75%) and placed on a self-regulating rectal probe-coupled heat
mat (TC-1000; CWE) to maintain a body temperature of 37°C. To
minimise air contact of arterial bloods during measurements, the
right carotid artery was cannulated with a mouse arterial catheter
(MAC-02; SAI Infusion Technologies) pre-flushed with 10 U
heparin-0.9% w/v saline to prevent clots. Blood was released
via the catheter into the EC8+ cartridge for analysis on the iSTAT
(Abaxsis). Post-surgery additional blood was collected by using
Microvette CB 300 LH (Sarstedt) and centrifuged at 2,000 g for
5 min to extract plasma before storage at 80°C. Plasma aldos-
terone was calculated by HTRF (homogeneous time-resolved fluo-
rescence) aldosterone assay (Cisbio, Codolet, France), according to
the manufacturer’s protocol using the PheraStar FS (BMG Labtech)
plate reader.
To determine plasma and urine electrolyte homoeostasis,
animals were placed on a 0.3% w/w Na diet for 2 weeks with
urine and plasma time-matched samples collected between days 7
and 10 for normal Na (NNa) diet baseline. On day 14, mice were
switched onto a 0.03% w/w Na diet with sampling repeated on
days 7–10 for low-Na (LNa) diet measurements. Spot urine was
collected from awake mice following spontaneous micturition on
handling over a sheet of Saran wrap or Parafilm. Samples were
then divided, and one sample received acidification with HNO3 to
a final concentration of 1% v/v to prevent precipitation of elec-
trolytes, before both were stored at 80°C. Blood was collected by
saphenous venepuncture in awake restrained animals, and plasma
was separated and stored in a similar fashion to that described
above. Plasma and urine (non-acidified) creatinine levels were
assayed in the Core Biochemical Assay Laboratory, Addenbrooke’s
Hospital, Cambridge, UK. Plasma and urine (acidified) samples
were diluted 1:1,000 using ultrapure polished water containing 1%
v/v HNO3. Cations were then measured by inductively coupled
plasma-optical emission spectrometry (Perkin Elmer ICP-OES Anal-
yser) with known concentration standards and preset elemental
spectra. Data collection and analysis were carried out in a blinded
fashion throughout.
Statistical analysis
Data presented are mean  standard error of the mean (SEM),
unless otherwise stated. Statistical analyses were performed on
either SPSS version 22 or GraphPad Prism (http://www.graph
pad.com/scientific-software/prism/) software. Two-tailed Student’s
t-tests were performed either paired or unpaired where appropriate.
P < 0.05 was taken as statistically significant throughout.
For MYPT1 phosphorylation quantification (Appendix Fig S6),
ratiometric expression was calculated for CUL3WT/D403–459 versus
CUL3WT on each Western blot of independent biological replicates.
The mean of the ratios and bounds of the 95% confidence interval
were calculated, where ratio = 1 represents no change in phosphory-
lation and ratio > 1 represents an increase in the phosphoryla-
tion status of CUL3WT/D403–459 mice. Statistical significance was
determined by the ratio t-test (http://www.wormbook.org/chapters/
www_statisticalanalysis/statisticalanalysis.html).
Expanded View for this article is available online:
http://embomolmed.embopress.org
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